ELOTUZUMAB
Manufacturer: E.R. Squibb & Sons, L.L.C.
Score: 141.0
EMPLICITI (elotuzumab) is a humanized monoclonal antibody used in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies, and in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. The recommended dosage is 10 mg/kg administered intravenously every week for the first two cycles and every 2 weeks thereafter until disease progression or unacceptable toxicity. Premedication with dexamethasone, diphenhydramine, ranitidine, and acetaminophen is required. The most common adverse reactions include fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, and pneumonia.
No specific warning mentioned
Dose delays and modifications for dexamethasone, pomalidomide, and lenalidomide should be performed as recommended in their Prescribing Information
10 mg/kg administered intravenously every week for the first two cycles and every 2 weeks thereafter
Not established